Cost-utility analysis of newborn screening for spinal muscular atrophy in Japan
NBS for SMA allows for early identification of patients with SMA and treatment initiation before symptom onset, improving health outcomes and reducing total costs than without NBS.
Authors
- Satoru Tanaka (ORCID: https://orcid.org/0000-0003-3204-1790)
- Laëtitia Schmitt (ORCID: https://orcid.org/0000-0003-1052-488X)
- M Bischof
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Walter Toro (ORCID: https://orcid.org/0000-0002-5369-497X)
- Akira Hata (ORCID: https://orcid.org/0000-0003-0867-3704)
- Diana Weidlich
- Akihito Uda (ORCID: https://orcid.org/0000-0002-4880-1195)
Institutions
- Novartis (Switzerland) (CH)
- Office of Disease Prevention and Health Promotion (US)
- Novartis (Japan) (JP)
- Novartis (United States) (US)
- Clarivate (United States) (US)
- Novartis Gene Therapies Switzerland GmbH
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1080/13696998.2024.2439734
- Citations
- 3
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 1.31